Kinnov Therapeutics

Kinnov Therapeutics

First-in-class therapy for a worldwide market

Menu

  • Company
  • R&D
  • Product KT-110
  • Partners
  • News
  • Contact us

logo_les_echos

 

art_les_echosCliquer ici pour accéder à l’article dans Les Echos.

Kinnov-Therapeutics announces the completion of patient recruitment in the alcohol use disorder study (COCKTAIL).
Tagged on: addiction    alcohol    alcool    clinical trial    essais cliniques
kinnov September 9, 2021 news
  • ← Kinnov Therapeutics sera présent au 3ème congrès international Socidrogalcohol
  • Encouraging Results in Kinnov Phase II study ! →

Co-funded by the horizon 2020 programme of the European Union

About us

Kinnov Therapeutics is dedicated to the R&D of innovative therapies against addiction. Supported by experienced scientists in the drug discovery and development, we have identified the key receptors of addiction. KT-110, our first-in-class lead composition, has been tested in phase 2 clinical trial for alcohol addiction.

Contact Us

Kinnov-Therapeutics

3, allée du titane
45100 Orléans, France


View Larger Map

Pages

  • Addictions: a major Public Health threat
  • Company
  • Contact us
  • Home
  • Partners
  • Preclinical trials
  • Product KT-110
  • R&D

Copyright 2020 - Kinnov Therapeutics